224 related articles for article (PubMed ID: 35708137)
1. Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning.
Eckardt JN; Röllig C; Metzeler K; Kramer M; Stasik S; Georgi JA; Heisig P; Spiekermann K; Krug U; Braess J; Görlich D; Sauerland CM; Woermann B; Herold T; Berdel WE; Hiddemann W; Kroschinsky F; Schetelig J; Platzbecker U; Müller-Tidow C; Sauer T; Serve H; Baldus C; Schäfer-Eckart K; Kaufmann M; Krause S; Hänel M; Schliemann C; Hanoun M; Thiede C; Bornhäuser M; Wendt K; Middeke JM
Haematologica; 2023 Mar; 108(3):690-704. PubMed ID: 35708137
[TBL] [Abstract][Full Text] [Related]
2. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Relevance of DNMT3A, FLT3 and NPM1 Mutations in Syrian Acute Myeloid Leukemia Patients.
Moualla Y; Moassass F; Al-Halbi B; Al-Achkar W; Georgeos M; Yazigi H; Khamis A
Asian Pac J Cancer Prev; 2022 Apr; 23(4):1387-1395. PubMed ID: 35485701
[TBL] [Abstract][Full Text] [Related]
4. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
5. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
[TBL] [Abstract][Full Text] [Related]
6. FLT3-ITD and CEBPA Mutations Predict Prognosis in Acute Myelogenous Leukemia Irrespective of Hematopoietic Stem Cell Transplantation.
Wang H; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
Biol Blood Marrow Transplant; 2019 May; 25(5):941-948. PubMed ID: 30503388
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients.
Elrhman HAEA; El-Meligui YM; Elalawi SM
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e960-e969. PubMed ID: 34376373
[TBL] [Abstract][Full Text] [Related]
8. Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.
Wen XM; Lin J; Yang J; Yao DM; Deng ZQ; Tang CY; Xiao GF; Yang L; Ma JC; Hu JB; Qian W; Qian J
Int J Clin Exp Pathol; 2014; 7(10):6832-40. PubMed ID: 25400766
[TBL] [Abstract][Full Text] [Related]
9. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
11. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.
Ohgami RS; Ma L; Merker JD; Gotlib JR; Schrijver I; Zehnder JL; Arber DA
Mod Pathol; 2015 May; 28(5):706-14. PubMed ID: 25412851
[TBL] [Abstract][Full Text] [Related]
12. Chromosomal Abnormalities and Prognosis in
Angenendt L; Röllig C; Montesinos P; Martínez-Cuadrón D; Barragan E; García R; Botella C; Martínez P; Ravandi F; Kadia T; Kantarjian HM; Cortes J; Juliusson G; Lazarevic V; Höglund M; Lehmann S; Recher C; Pigneux A; Bertoli S; Dumas PY; Dombret H; Preudhomme C; Micol JB; Terré C; Ráčil Z; Novák J; Žák P; Wei AH; Tiong IS; Wall M; Estey E; Shaw C; Exeler R; Wagenführ L; Stölzel F; Thiede C; Stelljes M; Lenz G; Mikesch JH; Serve H; Ehninger G; Berdel WE; Kramer M; Krug U; Schliemann C
J Clin Oncol; 2019 Oct; 37(29):2632-2642. PubMed ID: 31430225
[TBL] [Abstract][Full Text] [Related]
13. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia.
Eckardt JN; Stasik S; Röllig C; Petzold A; Sauer T; Scholl S; Hochhaus A; Crysandt M; Brümmendorf TH; Naumann R; Steffen B; Kunzmann V; Einsele H; Schaich M; Burchert A; Neubauer A; Schäfer-Eckart K; Schliemann C; Krause SW; Herbst R; Hänel M; Hanoun M; Kaiser U; Kaufmann M; Rácil Z; Mayer J; Oelschlägel U; Berdel WE; Ehninger G; Serve H; Müller-Tidow C; Platzbecker U; Baldus CD; Dahl A; Schetelig J; Bornhäuser M; Middeke JM; Thiede C
Leukemia; 2023 Dec; 37(12):2395-2403. PubMed ID: 37833543
[TBL] [Abstract][Full Text] [Related]
14. [NPM1 and CEBPA mutations in pediatric cytogenetically normal acute myeloid leukemia].
Ruan M; Zhang L; Han C; Liu X; Ai X; Zhang J; Liu T; Yang W; Chen X; Guo Y; Wang S; Li Q; Zou Y; Chen Y; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Apr; 52(4):303-7. PubMed ID: 24915920
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
[TBL] [Abstract][Full Text] [Related]
17. [C-kit, NPM1 and FLT3 gene mutation patterns and their prognostic significance in 656 Chinese patients with acute myeloid leukemia].
Ding ZX; Shen HJ; Miao JC; Chen SN; Qiu QC; Qi XF; Jin ZM; Wu DP; He J
Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):829-34. PubMed ID: 23384905
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations.
Heidrich K; Thiede C; Schäfer-Eckart K; Schmitz N; Aulitzky WE; Krämer A; Rösler W; Hänel M; Einsele H; Baldus CD; Trappe RU; Stölzel F; Middeke JM; Röllig C; Taube F; Kramer M; Serve H; Berdel WE; Ehninger G; Bornhäuser M; Schetelig J;
Ann Oncol; 2017 Nov; 28(11):2793-2798. PubMed ID: 28945881
[TBL] [Abstract][Full Text] [Related]
19. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients.
Tien FM; Hou HA; Tsai CH; Tang JL; Chen CY; Kuo YY; Li CC; Lin CT; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Tseng MH; Liu MC; Liu CW; Lin LI; Chou WC; Tien HF
Eur J Haematol; 2018 Jul; 101(1):86-94. PubMed ID: 29624746
[TBL] [Abstract][Full Text] [Related]
20. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
